Literature DB >> 24276885

Plasticity of airway lymphatics in development and disease.

Li-Chin Yao1, Donald M McDonald.   

Abstract

The dynamic nature of lymphatic vessels is reflected by structural and functional modifications that coincide with changes in their environment. Lymphatics in the respiratory tract undergo rapid changes around birth, during adaptation to air breathing, when lymphatic endothelial cells develop button-like intercellular junctions specialized for efficient fluid uptake and transport. In inflammatory conditions, lymphatic vessels proliferate and undergo remodeling to accommodate greater plasma leakage and immune cell trafficking. However, the newly formed lymphatics are abnormal, and resolution of inflammation is not accompanied by complete reversal of the lymphatic vessel changes back to the baseline. As the understanding of lymphatic plasticity advances, approaches for eliminating the abnormal vessels and improving the functionality of those that remain move closer to reality. This chapter provides an overview of what is known about lymphatic vessel growth, remodeling, and other forms of plasticity that occur during development or inflammation, with an emphasis on the respiratory tract. Also addressed is the limited reversibility of changes in lymphatics during the resolution of inflammation.

Entities:  

Mesh:

Year:  2014        PMID: 24276885      PMCID: PMC3955364          DOI: 10.1007/978-3-7091-1646-3_4

Source DB:  PubMed          Journal:  Adv Anat Embryol Cell Biol        ISSN: 0301-5556            Impact factor:   1.231


  61 in total

1.  Evidence for a second valve system in lymphatics: endothelial microvalves.

Authors:  J Trzewik; S K Mallipattu; G M Artmann; F A Delano; G W Schmid-Schönbein
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

2.  Angiogenesis and remodeling of airway vasculature in chronic inflammation.

Authors:  D M McDonald
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

3.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.

Authors:  T Mäkinen; L Jussila; T Veikkola; T Karpanen; M I Kettunen; K J Pulkkanen; R Kauppinen; D G Jackson; H Kubo; S Nishikawa; S Ylä-Herttuala; K Alitalo
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

4.  VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts.

Authors:  Ingrid Nilsson; Fuad Bahram; Xiujuan Li; Laura Gualandi; Sina Koch; Malin Jarvius; Ola Söderberg; Andrey Anisimov; Ivana Kholová; Bronislaw Pytowski; Megan Baldwin; Seppo Ylä-Herttuala; Kari Alitalo; Johan Kreuger; Lena Claesson-Welsh
Journal:  EMBO J       Date:  2010-03-11       Impact factor: 11.598

5.  VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins.

Authors:  Young-Kwon Hong; Bernhard Lange-Asschenfeldt; Paula Velasco; Satoshi Hirakawa; Rainer Kunstfeld; Lawrence F Brown; Peter Bohlen; Donald R Senger; Michael Detmar
Journal:  FASEB J       Date:  2004-05-07       Impact factor: 5.191

6.  Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.

Authors:  Marika J Karkkainen; Paula Haiko; Kirsi Sainio; Juha Partanen; Jussi Taipale; Tatiana V Petrova; Michael Jeltsch; David G Jackson; Marja Talikka; Heikki Rauvala; Christer Betsholtz; Kari Alitalo
Journal:  Nat Immunol       Date:  2003-11-23       Impact factor: 25.606

7.  Inhaled fluticasone propionate reduces concentration of Mycoplasma pneumoniae, inflammation, and bronchial hyperresponsiveness in lungs of mice.

Authors:  Hong Wei Chu; Jennifer A Campbell; John G Rino; Ronald J Harbeck; Richard J Martin
Journal:  J Infect Dis       Date:  2004-03-02       Impact factor: 5.226

8.  Therapeutic lymphangiogenesis with human recombinant VEGF-C.

Authors:  Andrzej Szuba; Mihaela Skobe; Marika J Karkkainen; William S Shin; David P Beynet; Ned B Rockson; Noma Dakhil; Stan Spilman; Michael L Goris; H William Strauss; Thomas Quertermous; Kari Alitalo; Stanley G Rockson
Journal:  FASEB J       Date:  2002-10-18       Impact factor: 5.191

9.  Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation.

Authors:  Reto Huggenberger; Stefan Ullmann; Steven T Proulx; Bronislaw Pytowski; Kari Alitalo; Michael Detmar
Journal:  J Exp Med       Date:  2010-09-13       Impact factor: 14.307

10.  Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.

Authors:  Janice A Nagy; Eliza Vasile; Dian Feng; Christian Sundberg; Lawrence F Brown; Michael J Detmar; Joel A Lawitts; Laura Benjamin; Xiaolian Tan; Eleanor J Manseau; Ann M Dvorak; Harold F Dvorak
Journal:  J Exp Med       Date:  2002-12-02       Impact factor: 14.307

View more
  5 in total

1.  Lymphangiogenesis in rat asthma model.

Authors:  Aigul Moldobaeva; John Jenkins; Qiong Zhong; Elizabeth M Wagner
Journal:  Angiogenesis       Date:  2016-10-27       Impact factor: 9.596

Review 2.  Lymphatic Dysfunction, Leukotrienes, and Lymphedema.

Authors:  Xinguo Jiang; Mark R Nicolls; Wen Tian; Stanley G Rockson
Journal:  Annu Rev Physiol       Date:  2017-10-13       Impact factor: 19.318

3.  Cocaine enhances HIV-1 gp120-induced lymphatic endothelial dysfunction in the lung.

Authors:  Xuefeng Zhang; Susan Jiang; Jinlong Yu; Paula M Kuzontkoski; Jerome E Groopman
Journal:  Physiol Rep       Date:  2015-08

4.  Transcriptional landscape of pulmonary lymphatic endothelial cells during fetal gestation.

Authors:  Timothy A Norman; Adam C Gower; Felicia Chen; Alan Fine
Journal:  PLoS One       Date:  2019-05-13       Impact factor: 3.240

5.  Signaling of Prostaglandin E Receptors, EP3 and EP4 Facilitates Wound Healing and Lymphangiogenesis with Enhanced Recruitment of M2 Macrophages in Mice.

Authors:  Kanako Hosono; Risa Isonaka; Tadashi Kawakami; Shuh Narumiya; Masataka Majima
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.